Clinical Trial Update: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Apatinib in combination with ifosfamide and etoposide (OAIE) for relapsed or refractory osteosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Apatinib (apatinib)
• Etoposide (Etoposide)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Effect of Drug, Drug | Phase 2 | Status: COMPLETED